Atai Life Sciences N.V., a clinical-stage biopharmaceutical company developing psychedelic treatments for mental health disorders, reported a USD 26.3 million net loss in Q3 2024.
However, during the quarter, the company highlighted several key advancements in its research pipeline, including receiving FDA approval to advance Phase II trials for VLS-01 buccal film DMT, which targets treatment-resistant depression, and EMP-01, which treats social anxiety disorder.
The company remains optimistic about its extensive pipeline and expects promising results from its upcoming clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.